Average deductibles for Obamacare bronze plans will top $6,000 for individuals for the first time next year. » Read More
It has received subpoenas requesting information about its relationship with pharma companies, foundations and specialty pharmacies.
Financial advisors warn that near-certain high medical costs should be a key line item in any investor's retirement plan.
Top-ranked analyst Irina Koffler of Mizuho Securities initiated shares of Mylan with a buy rating on Wednesday.
Donald Trump has said in the past his workers get health coverage from their jobs, and this means they wouldn't have to buy Obamacare plans.
Mylan has raised prices of the anti-allergy device more than 500 percent in recent years.
Window shopping for health plans for 2017 began Monday on the federal Obamacare exchange HealthCare.gov.
Unlike an flexible savings account, health savings account funds don't expire at the end of the year and they're portable.
Sen. Bernie Sanders and Rep. Elijah Cummings request details after Ariad repeatedly raised the price of its drug.
A new drug being tested slows Alzheimer's by removing plaque buildup in the brain. It's hope for millions suffering from the disease.
New CEO David Sacks is hoping that a new all-in-one human resources platform for small business will turn the page for Zenefits in 2017.
Eli Lilly is expanding its international operations to target diabetes and tuberculosis in areas lacking access to treatment.
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
A cybersecurity expert explains to CNBC why a breach of a medical device maker could be a new front in the hacking wars.
Martin Shkreli's lawyers previously suggested that his defense would be based on the claim that he had been relying on the advice of his lawyer.
"Pharma bro" Martin Shkreli wanted to visit a Brooklyn bar immediately after his hearing in Brooklyn Friday afternoon, but one establishment put a stop to that.
Medicare ratings cuts at Humana may signal a higher bar for other Medicare insurers, an analyst says.
Get the best of CNBC in your inbox